恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的临床效果

Clinical effect of Entecavir in the treatment of chronic hepatitis B combined with hepatic steatosis

目的探讨恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的临床效果。方法选取2017年2～11月我院收治的80例慢性乙型肝炎合并肝脂肪变患者作为研究对象,按照电脑随机分配方法将其分为观察组(40例)与对照组(40例)。观察组患者采用恩替卡韦治疗,对照组患者采用瑞舒伐他汀治疗。比较两组患者的血清丙氨酸氨基转移酶和乙型肝炎病毒-DNA、血脂指标、治疗效果。结果治疗后,观察组患者的血清丙氨酸氨基转移酶、乙型肝炎病毒-DNA低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者的总胆固醇、三酰甘油及低密度脂蛋白胆固醇低于对照组,高密度脂蛋白胆固醇高于对照组,差异有统计学意义(P<0.05);观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果十分显著,能够使其血脂指标得到改善,值得研究。

Objective To investigate the clinical effect of Entecavir in the treatment of chronic hepatitis B with hepatic steatosis.Methods Eighty patients with chronic hepatitis B and hepatic steatosis admitted to our hospital from February to November in 2017 were aelected as subjects.The patients were equally divided into observation group and control group according to computer randomization.In the observation group,Entecavir was used,and in the control group,Rosuvastatin was adopted.The serum alanine aminotransferase(ALT),hepatitis B virus-DNA,blood lipid index and therapeutic effect were compared between the two groups.Results After treatment,the serum ALT and hepatitis B virus-DNA of patients in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the total cholesterol,triglyceride and low density lipoprotein cholesterol in the observation group were lower than those in the control group,and the high density lipoprotein cholesterol was higher than that in the control group,the differences were statistically significant(P<0.05).The total effectiveness rate of the observation group was higher than that of the control group with a statistical difference(P<0.05).Conclusion The efficacy of Entecavir in the treatment of chronic hepatitis B with hepatic steatosis is very significant,which can improve the blood lipid index,and is worthy of study.